The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

NFL News: Andy Reid's Chiefs sign a key veteran to help Patrick Mahomes, Travis Kelce The Ocean Has Massive Energy Reserves.

Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

FRANKFURT (Reuters) - The CEO of Roche said more cases of mpox infection have likely occurred in Europe than previously ...

Roche's third-quarter sales gained a currency-adjusted 9%, beating market expectations, on higher prescriptions of ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

Roche Holding (RHHBF) reaffirms full-year sales and earnings outlook after its Q3 results exceeded Street forecasts. Read ...

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...